AVLN

Avalyn Pharma Inc. Common Stock NASDAQ

Healthcare ·Medical - Pharmaceuticals ·US · avalynpharma.com

$29.84

Mkt Cap $1.1B

52w Low $26.00 91.4% of range 52w High $30.20

50d MA $29.49 200d MA $29.49

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity —

ROE —

P/FCF —

RSI (14) —

ATR (14) —

Beta 0.00

50d MA $29.49

200d MA $29.49

Avg Volume —

About

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Recent Filings

8-K

Avalyn Pharma Inc. -- 8-K Filing

Avalyn Pharma completed its initial public offering and implemented new amended and restated bylaws effective upon IPO registration, establishing updated corporate governance procedures for the newly public company.

May 1

Data updated apr 30, 2026 4:11pm · Source: massive.com